From an economics perspective—a cost-benefit analysis—is the cost higher to purchase these things when the government has to engage in these special access requests, because they're not registered? If we were to lower the regulatory requirements for registration or the fees, do you think it would it actually save the Canadian government money in the long run, because they would have better access to these drugs?
On February 7th, 2019. See this statement in context.